Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVOK NYSE:STR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVOKEvoke Pharma$11.00+0.4%$10.90$2.28▼$11.00$18.92M-0.15983,927 shs47,100 shsSTRSitio Royalties$18.17-15.7%$0.00$16.70▼$20.78$2.73B1.521.42 million shs913,714 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVOKEvoke Pharma0.00%0.00%0.00%0.00%+266.67%STRSitio Royalties0.00%0.00%0.00%0.00%-10.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVOKEvoke Pharma$11.00+0.4%$10.90$2.28▼$11.00$18.92M-0.15983,927 shs47,100 shsSTRSitio Royalties$18.17-15.7%$0.00$16.70▼$20.78$2.73B1.521.42 million shs913,714 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVOKEvoke Pharma0.00%0.00%0.00%0.00%+266.67%STRSitio Royalties0.00%0.00%0.00%0.00%-10.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVOKEvoke Pharma 1.50ReduceN/AN/ASTRSitio Royalties 2.50Moderate Buy$27.0048.56% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVOKEvoke Pharma$10.25M1.85N/AN/A$4.74 per share2.32STRSitio Royalties$624.41M4.39$2.41 per share7.53$21.50 per share0.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVOKEvoke Pharma-$5.35M-$2.07N/AN/AN/A-36.23%-101.40%-31.86%N/ASTRSitio Royalties$40.95M-$0.0641.3129.79N/A6.06%1.12%0.79%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEVOKEvoke PharmaN/AN/AN/AN/AN/ASTRSitio Royalties$1.447.92%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVOKEvoke PharmaN/A1.271.22STRSitio Royalties0.334.044.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVOKEvoke PharmaN/ASTRSitio Royalties90.44%Insider OwnershipCompanyInsider OwnershipEVOKEvoke Pharma2.29%STRSitio Royalties0.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVOKEvoke Pharma41.72 million1.68 millionNot OptionableSTRSitio RoyaltiesN/A150.91 million149.76 millionOptionableGMR, WVIA, EVOK, and STR HeadlinesRecent News About These CompaniesDiamondback Energy's Viper Energy, Inc. Completes Acquisition of Sitio Royalties Corp. and Updates Q3 2025 Production GuidanceAugust 19, 2025 | quiverquant.comQViper Energy, Inc. Completes Acquisition of Sitio Royalties Corp. and Revises Q3 2025 Production GuidanceAugust 19, 2025 | quiverquant.comQSitio Royalties Approves Merger with Viper EnergyAugust 18, 2025 | tipranks.comSitio Royalties Corp. Stockholders Approve Merger with Viper Energy, Inc. | STR Stock NewsAugust 18, 2025 | gurufocus.comSitio Royalties Corp. Stockholders Approve Merger with Viper Energy, Inc.August 18, 2025 | gurufocus.comSitio Royalties Corp. Stockholders Approve Merger with Viper Energy, Inc.August 18, 2025 | businesswire.comRestrictive Merger Terms May Limit Sitio Royalties’ Strategic Options and Shareholder ValueAugust 8, 2025 | theglobeandmail.comWhat To Expect From Sitio Royalties Corp (STR) Q2 2025 EarningsAugust 7, 2025 | finance.yahoo.comSitio (STR) Q2 Revenue Beats EstimatesAugust 5, 2025 | theglobeandmail.comSitio Royalties (STR) Reports Q2 Earnings: What Key Metrics Have to SayAugust 4, 2025 | zacks.comSitio Royalties (STR) Beats Q2 Earnings and Revenue EstimatesAugust 4, 2025 | zacks.comSitio Royalties Reports Second Quarter 2025 Operational and Financial ResultsAugust 4, 2025 | businesswire.comBarclays Remains a Hold on Sitio Royalties (STR)July 30, 2025 | theglobeandmail.comAnalysts Estimate Sitio Royalties (STR) to Report a Decline in Earnings: What to Look Out forJuly 28, 2025 | zacks.comSITIO ROYALTIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sitio Royalties Corp. - STRJuly 21, 2025 | businesswire.comSitio Royalties Announces Revised Date for Second Quarter 2025 Earnings ReleaseJuly 21, 2025 | businesswire.comSitio Royalties Schedules Second Quarter 2025 Earnings ReleaseJuly 11, 2025 | businesswire.comBreaking Down Sitio Royalties: 4 Analysts Share Their ViewsJuly 9, 2025 | benzinga.comSitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shrJune 9, 2025 | uk.finance.yahoo.com$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sitio Royalties Corp. (NYSE: STR)June 9, 2025 | globenewswire.com Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemBy Dan Schmidt | May 30, 2026Fifth Third’s Big Bet Is OnBy Peter Frank | June 4, 2026GMR, WVIA, EVOK, and STR Company DescriptionsEvoke Pharma NASDAQ:EVOKEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Sitio Royalties NYSE:STRSitio Royalties Corp. operates as oil and gas mineral and royalty company. The company acquires oil-weighted rights in productive and the United States basins. It has approximately 140,000 net royalty acres through the consummation of over 180 acquisitions. The company was founded in 2016 and is headquartered in Denver, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
